Applied Filters
Why Novartis lost its treatment dispute with Teva
The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
Amgen v Sanofi: Big Pharma awaits SCOTUS decision
As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.
Exhaustion and parallel trade: what’s next for pharma TMs?
As the ‘UK+’ exhaustion regime is set to continue for now, Rebecca Anderson-Smith of Mewburn Ellis explores how pharma firms should protect their rights.
Navigating the murky waters of the Hatch-Waxman ‘safe harbour’
Safe harbour provisions can be relied on but their boundaries are still being defined, explain Jeanna Wacker and Tasha Francis Gerasimow of Kirkland & Ellis.
The increasing relevance of ‘technical character’
Two decisions from the European Patent Office offer important guidance for healthcare inventions that use computers, says Rosie McDowell of EIP.
CMA costs case improves access to justice
The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.
Gilenya injunction bid: big pharma takeaways
The England and Wales Patent Court affirmed its power to grant injunctions for pre-grant patents—but not for Novartis, explains Azadeh Vahdat of EIP.
Solving the PCT Priority problem
The ‘joint applicants’ approach to PCT applications would provide an elegant solution to issues of who is entitled to priority claims in PCT applications, suggests Chiara Banas of EIP.
When alliances fail, is arbitration the answer?
The global pandemic has increased collaboration and a new wave of disputes is likely. Arbitration is well placed to help, argue Kate Davies McGill, Gaela Gehring Flores and Paul Keller of Allen & Overy
Why mentorship matters
Effective support and guidance can achieve greater diversity in life sciences, say general counsel from Bristol Myers Squibb, AstraZeneca, The Chemours Company and Eli Lilly.
